To the Editor, Prostate cancer is an androgen-dependent disease and thus can be treated with androgen deprivation therapy (ADT). Patients on long-term ADT eventually develop castration-resistant prostate cancer (CRPC), an illness that is characterized by disease progression despite the presence of adequate testosterone suppression. In CRPC, sensitivity to hormonal manipulation may be maintained, although several mechanisms of resistance developed by the cancer cell exist [1] .
The growth mechanism for cancer cells in CRPC may include amplification and/or mutations of the androgen receptor; testosterone production by both intracellular activity of prostate cancer cells and by adrenal synthesis via dehydroepiandrosterone and androstenedione (these being weak androgens) could be an alternate mechanism of stimulating androgen receptor [2] .
A treatment approach to CRPC involves further endocrine manipulation with abiraterone acetate (AA, Zytiga ® ). AA prevents testicular and extragonadal androgen synthesis through irreversible inhibition of cytochrome P450-17A1 (CYP17A1). Blocking the 17α-hydroxylase and 17-20 lyase activity of CYP17 results in inhibition of DHEA and androstenedione production from pregnenolone, and finally testosterone synthesis suppression [3, 4] .
AA has demonstrated survival benefits in both castration-sensitive and castration-resistant prostate cancer patients and it is an approved standard of care [5] . The biochemical response assessment to therapy is evaluated by monitoring prostate-specific antigen (PSA) and testosterone levels.
Recently Fairfaix et al. [6] reported a possible interference of AA on the testosterone determination with Abbot reagent. Nevertheless, in the Fairfaix et al. study the interference was measured only indirectly, evaluating abnormally high testosterone concentration in patients while on therapy. For the same clinical cases, testosterone concentrations were obtained with new reagent release, measuring values congruent with the clinical situation.
In our work, we evaluated the possible cross-reaction caused by abiraterone, the active metabolite of AA, on the Access Testosterone assay (Beckman Coulter Inc., Fullerton, CA, USA) performed on DxI 800 platform. The crossreaction was evaluated by a displacement curve, assaying different abiraterone concentrations with testosterone reagent, and evaluating the ratio between the levels of abiraterone and testosterone that cause the halving of the binding capacity with respect to "zero" dose [7] .
Abiraterone (Cayman Chemical, Ann Arbor, MI, USA), the active metabolite of AA, was dissolved in ethanol to the concentration of 1 mg/mL, and subsequently diluted with the standard zero of testosterone in order to prepare two different tests, with the following concentrations: 143.1-57.2-28.6-14.3-5.72-1.43-0.57-0.14-0.057 μmol/L for the first test and 286.1-143.1-57.2-28.6-14.3-5.72-1.43 μmol/L for the second test.
Access Testosterone Assay (Beckman Coulter Inc., Fullerton, CA, USA) was performed according to the manufacturer's instruction, and showed a limit of quantitation (LoQ) of 0.5 nmol/L [7] . Both the calibration curves of testosterone and the abiraterone curves were interpolated by a four-parameter logistic curve. The concentrations halving the binding capacity with respect to the testosterone zero dose in the two experiment was 2.6 nmol/L and 2.41 nmol/L for testosterone and 152 μmol/L and 168 μmol/L for abiraterone, respectively. Then, the relative cross-reaction of the abiraterone in e254 Dittadi et al.: Abiraterone and testosterone immunoassay the testosterone assay resulted in 0.0017% and 0.0014%, respectively (Figure 1 ).
We then established the possible interference with a direct evaluation of cross-reaction by the displacement curve. The indirect determination of possible interference on testosterone measurement can be misleading if evaluated in patients on AA treatment. In fact, testosterone measurement can be partly biased, mainly due to problems of adherence to or wrong administration of ADT, i.e. LHRH-agonist injection [8] . Moreover, the addition of dexamethasone or prednisone/prednisolone to AA prevents that the inhibition of 17α-hydroxylase activity, leading to a reduction of cortisol, results in an increase of ACTH and therefore that of corticosterone. Then, the interference would not be due to the possible presence of a high concentration of testosterone precursors, but only due to a direct cross-reactivity of the drug, given the similar steroidal structure.
The measured cross-reaction was particularly low, with an interference measurable (apparent testosterone concentration over the LoQ) only at drug concentration >15 μmol/L; this would not be achievable in clinical practice. In fact, the higher concentrations of abiraterone measured in vivo, and mainly immediately after drug administration, resulted <5 μmol/L [9, 10] .
We conclude that periodic testosterone levels monitoring in patients treated with AA can be carried out without analytical drawbacks, at least with the method used in this study. The standard curves of testosterone (filled squares) and abiraterone prepared in testosterone-free matrix (filled circles and triangles) were assayed with testosterone reagent and the results were reported as percentage of bound(B)/B 0 . The cross-reactivity was defined as a percentage of the concentration of abiraterone at the point where the reduction in signal reach the 50% of the binding capacity (50% of the signal achieved in the absence of analyte), respect to the concentration of testosterone giving the same fall in signal. The concentrations are indicated by the arrows.
